The K-Ras(G12D)-inhibitory peptide KS-58 suppresses growth of murine CT26 colorectal cancer cell-derived tumors
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The K-Ras(G12D)-inhibitory peptide KS-58 suppresses growth of murine CT26 colorectal cancer cell-derived tumors
Authors
Keywords
-
Journal
Scientific Reports
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-05-17
DOI
10.1038/s41598-022-12401-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer
- (2021) Jens Köhler et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy
- (2021) David M. Briere et al. MOLECULAR CANCER THERAPEUTICS
- Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers
- (2021) David H. Peng et al. Nature Communications
- Selective and noncovalent targeting of RAS mutants for inhibition and degradation
- (2021) Kai Wen Teng et al. Nature Communications
- Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy
- (2021) Yujue Wang et al. CANCER CELL
- Drugging the Undruggable: Advances on RAS Targeting in Cancer
- (2021) Miriam Molina-Arcas et al. Genes
- On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma
- (2021) Colin R. Lindsay et al. LUNG CANCER
- Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non–small cell lung cancer
- (2020) Eri Sugiyama et al. Science Immunology
- RAS-targeted therapies: is the undruggable drugged?
- (2020) Amanda R. Moore et al. NATURE REVIEWS DRUG DISCOVERY
- Cyclic peptide FXII inhibitor provides safe anticoagulation in a thrombosis model and in artificial lungs
- (2020) Jonas Wilbs et al. Nature Communications
- Generation of KS-58 as the first K-Ras(G12D)-inhibitory peptide presenting anti-cancer activity in vivo
- (2020) Kotaro Sakamoto et al. Scientific Reports
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- A Comparative Analysis of Individual RAS Mutations in Cancer Biology
- (2019) Carmen Muñoz-Maldonado et al. Frontiers in Oncology
- SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
- (2018) Mingxia Zhao et al. Acta Pharmaceutica Sinica B
- Crystal Structure of a Human K-Ras G12D Mutant in Complex with GDP and the Cyclic Inhibitory Peptide KRpep-2d
- (2017) Satoshi Sogabe et al. ACS Medicinal Chemistry Letters
- Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides
- (2017) Alessandro Zorzi et al. Nature Communications
- Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP
- (2015) John C McGrath et al. BRITISH JOURNAL OF PHARMACOLOGY
- Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma
- (2014) John C Castle et al. BMC GENOMICS
- A Comprehensive Survey of Ras Mutations in Cancer
- (2012) I. A. Prior et al. CANCER RESEARCH
- Animal research: Reporting in vivo experiments: The ARRIVE guidelines
- (2010) Carol Kilkenny et al. BRITISH JOURNAL OF PHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started